CAR-T cell therapy for patients with extramedullary multiple myeloma：Opportunities and challenges

IF 7.6 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2025-03-21 DOI:10.1016/j.ejca.2025.115374

Yin Wang , Xiaoli Hu , Juan Du , Bei Liu

{"title":"CAR-T cell therapy for patients with extramedullary multiple myeloma：Opportunities and challenges","authors":"Yin Wang , Xiaoli Hu , Juan Du , Bei Liu","doi":"10.1016/j.ejca.2025.115374","DOIUrl":null,"url":null,"abstract":"<div><div>Multiple myeloma (MM) is a hematological malignancy characterized by abnormal proliferation of clonal plasma cells, which is usually confined to the bone marrow (BM). But some malignant plasma cells grow independently of the BM, called extramedullary disease (EMD). With the clinical application of proteasome inhibitors, immunomodulators, monoclonal antibodies, and hematopoietic stem cell transplantation, the overall survival of MM patients has been significantly improved, but the survival of patients with EMD is still worse than that of non-EMD patients. There are currently no specific treatment options for EMD. chimeric antigen receptor T (CAR-T) cell therapy has brought a new era of immunotherapy. The application of CAR-T has significantly benefited many MM patients, and CAR-T may be a new hope for patients with EMD in the future. This review retrospectively summarizes the mechanism and prognosis of EMD, focusing on the application and potential of CAR-T in the treatment of EMD. It is hoped that this review can provide ideas for the treatment of EMD with CAR-T in the future.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115374"},"PeriodicalIF":7.6000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804925001558","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Multiple myeloma (MM) is a hematological malignancy characterized by abnormal proliferation of clonal plasma cells, which is usually confined to the bone marrow (BM). But some malignant plasma cells grow independently of the BM, called extramedullary disease (EMD). With the clinical application of proteasome inhibitors, immunomodulators, monoclonal antibodies, and hematopoietic stem cell transplantation, the overall survival of MM patients has been significantly improved, but the survival of patients with EMD is still worse than that of non-EMD patients. There are currently no specific treatment options for EMD. chimeric antigen receptor T (CAR-T) cell therapy has brought a new era of immunotherapy. The application of CAR-T has significantly benefited many MM patients, and CAR-T may be a new hope for patients with EMD in the future. This review retrospectively summarizes the mechanism and prognosis of EMD, focusing on the application and potential of CAR-T in the treatment of EMD. It is hoped that this review can provide ideas for the treatment of EMD with CAR-T in the future.

查看原文本刊更多论文

CAR-T细胞治疗髓外多发性骨髓瘤：机遇与挑战

多发性骨髓瘤（MM）是一种以克隆浆细胞异常增殖为特征的血液系统恶性肿瘤，通常局限于骨髓（BM）。但一些恶性浆细胞独立于骨髓生长，称为髓外疾病（EMD）。随着蛋白酶体抑制剂、免疫调节剂、单克隆抗体和造血干细胞移植的临床应用，MM患者的总体生存得到了明显改善，但EMD患者的生存仍比非EMD患者差。目前尚无针对EMD的具体治疗方案。嵌合抗原受体T （CAR-T）细胞疗法带来了免疫治疗的新时代。CAR-T的应用使许多MM患者明显受益，CAR-T可能是未来EMD患者的新希望。本文回顾总结了EMD的发生机制和预后，重点介绍了CAR-T在EMD治疗中的应用和潜力。希望本综述能为今后CAR-T治疗EMD提供思路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.